NCT02848001终止1 期
A Phase 1, Open-label, Dose Finding Study of CC-90009, a Novel Cereblon E3 Ligase Modulating Drug, in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- Celgene
- 入组人数
- 101
- 试验地点
- 20
- 主要终点
- Number of Participants With Dose Limiting Toxicity (DLTs)
研究概览
简要总结
CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects with relapsed or refractory acute myeloid leukemia and relapsed or refractory higher-risk myelodysplastic syndrome.
详细描述
Study CC-90009-AML-001 is an open-label, Phase 1, dose escalation and expansion, first-in-human clinical study of CC-90009 in subjects with relapsed or refractory acute myeloid leukemia (AML) and relapsed or refractory higher-risk myelodysplastic syndrome.
The dose escalation part (Part A) of the study will evaluate the safety and tolerability of escalating doses of CC-90009 in relapsed and refractory AML. The expansion part, (Part B), will further evaluate the safety and efficacy of CC-90009 administered at or below the maximum tolerated dose (MTD) in selected expansion cohorts of one or more dosing regimens in order to determine the recommended Phase 2 dose (RP2D) for subjects with relapsed or refractory AML and relapsed or refractory higher-risk myelodysplastic syndrome.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women ≥ 18 years of age, at the time of signing the ICD (Informed Consent Document).
- •Subject must understand and voluntarily sign an ICD prior to any study-related assessments/procedures being conducted.
- •Relapsed or refractory AML (Acute Myeloid Leukemia) (Parts A and B) or relapsed or refractory (R/R) higher-risk MDS (Myelodysplastic Syndrome) (HR-MDS) (Part B only) as defined by World Health Organization criteria who are not suitable for other established therapies.
- •In Part A, R/R AML
- •In Part B, R/R AML including
- •Relapsed after allogeneic HSCT or
- •In second or later relapse or
- •Refractory to initial induction or re-induction treatment or
- •Refractory or relapse after HMA treatment (HMA failure defined as primary progression or lack of clinical benefit after a minimum of 6 cycles or unable to tolerate HMA due to toxicity) or
- •Refractory within 1 year of initial treatment (excluding those with favorable risk based on cytogenetics)
- •In Part B, R/R HR-MDS (Revised International Prognostic Scoring System score (IPSS-R) > 3.5 points, IPSS-R calculated during screening period):
- •IPSS-R intermediate risk (in combination with more than 10% bone marrow blasts or poor or very poor IPSS-R cytogenetic risk) or
- •IPSS-R high or
- •IPSS-R very high risk
- •Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to
- •At least 4 weeks (from first dose) has elapsed from donor lymphocyte infusion (DLI) without conditioning.
- •Subjects must have the following screening laboratory values:
- •Corrected serum Ca or free (ionized) serum Ca within normal limits (WNL).
- •o Corrected Ca (mg/dL) = Total Ca (mg/dL) - 0.8 (albumin [g/dL] - 4)
- •Total White Blood Cell count (WBC) < 25 x 10^9/L prior to first infusion. Prior or concurrent treatment with hydroxyurea to achieve this level is allowed.
- •Potassium and magnesium within normal limits or correctable with supplements.
- •Aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT) or alanine aminotransferase/serum glutamate pyruvic transaminase (ALT/SGPT) ≤ 2.5 x Upper Limit of Normal (ULN).
- •Uric acid ≤ 7.5 mg/dL (446 μmol/L). Prior and/or concurrent treatment with hypouricemic agents (eg, allopurinol, rasburicase) are allowed.
- •Selected electrolytes within normal limits or correctable with supplements.
- •Serum bilirubin ≤ 1.5 x ULN (upper limit of normal).
- •Estimated serum creatinine clearance of ≥ 60 mL/min using the Cockcroft-Gault equation. Measured creatinine clearance from a 24-hour urine collection is acceptable if clinically indicated.
- •International normalized ratio (INR) < 1.5 x ULN and Partial thromboplastin time (PTT) < 1.5 x ULN.
排除标准
- •Subjects with acute promyelocytic leukemia (APL)
- •Subjects with clinical symptoms suggesting active central nervous system (CNS) leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid is only required if there is clinical suspicion of CNS involvement by leukemia during screening.
- •Patients with prior autologous hematopoietic stem cell transplant who, in the investigator's judgment, have not fully recovered from the effects of the last transplant (e.g., transplant related side effects).
- •Prior allogeneic hematopoietic stem cell transplant (HSCT) with either standard or reduced intensity conditioning ≤ 6 months prior to starting CC-
- •Subjects on systemic immunosuppressive therapy post HSCT at the time of screening, or with clinically significant graft-versus-host disease (GVHD).
- •Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives or 4 weeks prior to starting CC-90009, whichever is shorter. Hydroxyurea is allowed to control peripheral leukemia blasts.
- •Leukapheresis ≤ 2 weeks prior to starting CC-90009.
研究组 & 干预措施
CC-90009 - Part A
Experimental
Will be administered intravenously per dosing schedule in a 28-day cycle.
干预措施: CC-90009 (Drug)
CC-90009 - Part B - AML and MDS patients
Experimental
Relapsed or refractory AML and MDS subjects. IP will be administered intravenously per dosing schedule determined in Part A
干预措施: CC-90009 (Drug)
结局指标
主要结局
Number of Participants With Dose Limiting Toxicity (DLTs)
时间窗: From first dose to at least 28 days and up to 42 days post first dose (Up to 42 days)
A participant evaluable for DLT is defined as one that: Has received at least 80% of the total planned Cycle 1 dose (eg, ≥ 4 CC-90009 doses for the Days 1-5 schedule to be completed on or before Day 10, ≥ 6 CC-90009 doses for the Days 1- 7 schedule to be completed on or before Day 10, ≥8 doses by Day 14 for the Days 1-10 schedule, or ≥ 5 doses by Day 14 for the D1-3/D8-10 schedule) of CC-90009 during Cycle 1 without experiencing a DLT, Or; Experienced a DLT after receiving at least one dose (or fraction thereof) of CC-90009 in part A.
次要结局
- Change From Baseline for Electrocardiogram (ECG) by Test - Parameters 2(From baseline until 28 days post last dose (Up to 25 months))
- Objective Response Rate (ORR)(Up to approximately 25 months after the last dose)
- Time to Remission/Response (TTR)(Up to approximately 25 months after the last dose)
- Renal Clearance (CLr)(Cycle 1 Day 1(C1D1). 1 cycle = 28 days)
- Non-Tolerated Dose (NTD) of CC-90009(From first dose to at least 28 days and up to 42 days post first dose (Up to 42 days))
- Change From Baseline by Laboratory Test - Chemistry Parameters 1(From baseline until 28 days post last dose (Up to 25 months))
- Maximum Tolerated Dose (MTD) of CC-90009(From first dose to at least 28 days and up to 42 days post first dose (Up to 42 days))
- Change From Baseline by Laboratory Test - Chemistry Parameters 3(From baseline until 28 days post last dose (Up to 25 months))
- Change From Baseline for Vital Signs by Test - Parameters 1(From baseline until 28 days post last dose (Up to 25 months))
- Change From Baseline for Vital Signs by Test - Parameters 2(From baseline until 28 days post last dose (Up to 25 months))
- Change From Baseline for Vital Signs by Test - Parameters 3(From baseline until 28 days post last dose (Up to 25 months))
- Change From Baseline for Electrocardiogram (ECG) by Test - Parameters 1(From baseline until 28 days post last dose (Up to 25 months))
- Eastern Cooperative Oncology Group (ECOG) Performance Status(From baseline until 28 days post last dose (Up to 25 months))
- Left Ventricular Ejection Fraction (LVEF) Percent Change From Baseline(From baseline until 28 days post last dose (Up to 25 months))
- Overall Survival (OS)(Up to approximately 25 months after the last dose)
- Relapse-free Survival (RFS)(Up to approximately 25 months after the last dose)
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs)(From first dose until 28 days post last dose (Up to 25 months))
- Event-free Survival (EFS)(Up to approximately 25 months after the last dose)
- Duration of Remission/Response (DOR)(Up to approximately 25 months after the last dose)
- Time to Acute Myeloid Leukemia (AML) Transformation(Up to approximately 88 months)
- Change From Baseline by Laboratory Test - Chemistry Parameters 2(From baseline until 28 days post last dose (Up to 25 months))
- Change From Baseline for Vital Signs by Test - Parameters 4(From baseline until 28 days post last dose (Up to 25 months))
- Progression-free Survival (PFS)(Up to approximately 25 months after the last dose)
- Maximum Observed Plasma Concentration (Cmax)(Cycle 1 Day 1(C1D1), C1D5, C1D7, C1D8, C1D10,)
- Complete Remission Rate (CRR)(Up to approximately 88 months)
- Total Body Clearance (CL)(Cycle 1 Day 1(C1D1), C1D5, C1D7, C1D8, C1D10. 1 cycle = 28 days)
- Time to Peak Plasma Concentration (Tmax)(Cycle 1 Day 1(C1D1), C1D5, C1D7, C1D8, C1D10. 1 cycle = 28 days)
- Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose (AUC 0 - 24)(Cycle 1 Day 1(C1D1), C1D5, C1D7, C1D8, C1D10. 1 cycle = 28 days)
- Terminal Phase Elimination Half-life (T1/2)(Cycle 1 Day 1(C1D1) and C1D5. 1 cycle = 28 days)
- Volume of Distribution (Vz)(Cycle 1 Day 1(C1D1) and C1D5. 1 cycle = 28 days)
研究者
研究点 (20)
Loading locations...
相似试验
终止
1 期
A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)Leukemia, Myeloid, AcuteMyelodysplastic SyndromesNCT02641002Celgene28
已完成
1 期
A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic CancersHematologic NeoplasmsNCT02367196Celgene60
终止
1 期
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's LymphomasLymphoma, Non-HodgkinNeoplasmsNCT03220347Celgene139
终止
1 期
Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic SyndromesLeukemia, Myeloid, AcuteMyelodysplastic SyndromesNCT04951778Celgene56
终止
1 期
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple MyelomaMultiple MyelomaNCT03486067Celgene183